Analysts at StockNews.com assumed coverage on shares of Organovo (NASDAQ:ONVO – Get Free Report) in a research note issued to investors on Thursday. The firm set a “sell” rating on the medical ...

On Friday, Organovo Holdings Inc (ONVO) stock saw a modest uptick, ending the day at $0.44 which represents no change from the prior close of of $0.44. The stock opened at $0.46 and touched a low of ...

Organovo (ONVO) announces that its oral presentation of its lead clinical stage drug FXR314 by Dr. Eric Lawitz of the Texas Liver Institute and the University of Texas Health San Antonio was ...

Organovo Holdings ( (ONVO) ) just unveiled an update.

SAN DIEGO, Nov. 20, 2024 (GLOBE NEWSWIRE) -- Organovo Holdings, Inc. (Nasdaq:ONVO), a clinical stage biotechnology company focused on developing novel treatment approaches in inflammatory bowel ...

Here's the latest reshuffling of top holdings by Soros Fund Management.

Organovo Holdings (NASDAQ:ONVO) is a biotechnology company that is both a developer of 3D tissue technology that has the potential to change the way treatments are discovered and tested ...

Shares of NASDAQ ONVO opened at $0.44 on Wednesday. Organovo has a 12-month low of $0.32 and a 12-month high of $1.74. The company has a market cap of $6.77 million, a P/E ratio of -0.42 and a ...

Detailed price information for Organovo Holdings (ONVO-Q) from The Globe and Mail including charting and trades.

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...